Hypothesis

In rheumatoid arthritis (RA), accumulation of p16^INK4a-positive senescent fibroblast-like synoviocytes (FLS) in the synovial lining creates a localized NAD+ sink via paracrine secretion of extracellular nicotinamide phosphoribosyltransferase (eNAMPT/visfatin). This eNAMPT acts as both a pro-inflammatory DAMP (activating TLR4 on macrophages) and an enzymatic drain on the nicotinamide mononucleotide (NMN) precursor pool, depleting intracellular NAD+ in neighboring non-senescent stromal cells. The resulting NAD+ deficit impairs SIRT1 deacetylase activity, preventing deacetylation of RelA/p65 at Lys310 and locking NF-κB in a constitutively active state. This creates a feed-forward loop: NF-κB drives further SASP cytokine release (IL-6, IL-1β, MMP-3), which accelerates senescence in adjacent FLS.

Key Prediction

Targeted clearance of senescent FLS with dasatinib+quercetin (D+Q) senolytics should restore synovial NAD+ levels measurably (quantifiable via ^31P-MRS or synovial fluid NAD+ metabolomics), reduce eNAMPT concentrations in synovial fluid, and reactivate SIRT1-dependent NF-κB silencing — resulting in flare suppression independent of conventional DMARDs.

Proposed Test

A proof-of-concept trial in RA patients with persistent synovitis despite methotrexate: (1) measure baseline synovial fluid eNAMPT, NAD+/NADH ratio, and p16^INK4a+ FLS fraction via ultrasound-guided biopsy; (2) administer intermittent D+Q (2 days on / 4 weeks off × 3 cycles); (3) repeat measurements at 12 weeks. Primary endpoint: ≥30% reduction in synovial fluid eNAMPT. Secondary: DAS28-CRP change, SIRT1 activity in biopsy samples.

Rationale

Senescent cells accumulate in RA joints (Del Rey et al., 2019; Chadha et al., 2023). eNAMPT is elevated in RA synovial fluid and correlates with disease activity. NAD+ depletion is a hallmark of aging tissues. SIRT1 deficiency exacerbates experimental arthritis in murine models. Yet no study has connected these observations into a unified senescence→NAD+ depletion→NF-κB loop specific to the RA synovium, nor tested whether senolytics can restore the NAD+ metabolome in an arthritic joint.

Limitations

• D+Q has systemic off-target effects; intra-articular delivery may be required
• eNAMPT has dual roles (enzymatic vs. cytokine-like) that are difficult to dissect in vivo
• ^31P-MRS spatial resolution may be insufficient for small joints
• Senescent FLS heterogeneity (p16 vs. p21 driven) could affect senolytic response